By Ben Glickman Coherus BioSciences received approval from the FDA for its on-body injector of Udenyca late Tuesday. The approval of the new presentation of.
Intel shares extend gains while Apple stock has declined for four straight sessions. A report says Tesla plans a revamped version of the Model Y from its.
Coherus BioSciences (NASDAQ:CHRS – Get Free Report)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research report issued on Wednesday, Benzinga reports. They presently have a $13.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective would indicate a potential upside of 496.33% from the company’s current […]
Truveta is a collaborative effort whose members include dozens of the largest healthcare systems in the U.S. It helps life sciences companies apply AI to a trove of
By Ben Glickman Shares of Coherus BioSciences rose late Tuesday after the company's on-body injector of Udenyca received approval from the U.S. Food and Drug.